The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...
FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo ...
The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...
Zacks Investment Research on MSN
AZN, Daiichi's Enhertu gets FDA nod for first-line breast cancer
AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody ...
Analysts at Jefferies called the approval "highly significant," estimating it could add $2 billion to $3 billion to peak ...
FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...
FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be ...
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research ...
Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day December 15, ...
Acupuncture may improve both perceived and objectively measured cognitive difficulties in breast cancer survivors, a ...
AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback